ArchiveAugust 2015

Fingolimod in the real world

Totaro R, Di Carmine C, Costantino G, Fantozzi R, Bellantonio P, Fuiani A, Mundi C, Ruggieri S, Marini C, Carolei A. Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.Mult Scler Int. 2015;2015:763418. doi: 10.1155/2015/763418. Objective. The aim of this prospective observational multicenter postmarketing study was...

Cell migration in Remyelination

Harlow DE, Saul KE, Komuro H, Macklin WB. Myelin Proteolipid Protein Complexes with αv Integrin and AMPA Receptors In Vivo and Regulates AMPA-Dependent Oligodendrocyte Progenitor Cell Migration through the Modulation of Cell-Surface GluR2 Expression. J Neurosci. 2015;35(34):12018-12032. In previous studies, stimulation of ionotropic AMPA/kainate glutamate receptors on cultured...

GABA as a neuroprotectant

Cawley N, Solanky BS, Muhlert N, Tur C, Edden RA, Wheeler-Kingshott CA, Miller DH, Thompson AJ, Ciccarelli O Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressivemultiple sclerosis.Brain. 2015;138(Pt 9):2584-95. doi: 10.1093/brain/awv209. Neurodegeneration is thought to be the major cause of ongoing, irreversible disability in progressive stages of...

imaging grey matter loss

Freeman L, Garcia-Lorenzo D, Bottin L, Leroy C, Louapre C, Bodini B, Papeix C, Assouad R, Granger B, Tourbah A, Dollé F, Lubetzki C, Bottlaender M, Stankoff B. The neuronal component of gray matter damage in multiple sclerosis: A [11C]-flumazenil positron emission tomography study.Ann Neurol. 2015 Aug. doi: 10.1002/ana.24468 OBJECTIVE:Using positron emission tomography (PET) with [11 C]flumazenil...

Low L-selectin as a risk factor for PML

Spadaro M, Caldano M, Marnetto F, Lugaresi A, Bertolotto A. Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells. J Neuroinflammation. 2015 Aug;12(1):146. doi: 10.1186/s12974-015-0365-x. BACKGROUND: The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. CD62L is involved in rolling and transmigration of...

Improved walking with medical cannabis

Coghe G, Pau M, Corona F, Frau J, Lorefice L, Fenu G, Spinicci G, Mamusa E, Musu L, Massole S, Massa R, Marrosu MG, Cocco E.J Walking improvements with nabiximols in patients with multiple sclerosis. Neurol. 2015 Aug 5. [Epub ahead of print] Recently, nabiximols was approved as a treatment in MS spasticity. Data leading to approval and clinical use of nabiximols, although widely...

Speed makes processing faster.

Morrow SA, Rosehart H. Effects of single dose mixed amphetamine salts – extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.Psychopharmacology (Berl). 2015 Aug. [Epub ahead of print] RATIONALE:Multiple sclerosis (MS) commonly affects cognitive function, most frequently presenting as impaired processing speed (PS). There are currently no...

Killing CD20 T cells

Holley JE, Bremer E, Kendall AC, de Bruyn M, Helfrich W, Tarr JM, Newcombe J, Gutowski NJ, Eggleton P. CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. Mult Scler Relat Disord. 2014;3(5):650-8. BACKGROUND: A subset of T-cells expresses the B-cell marker CD20 and in rheumatoid arthritis...

Are you being sold a curve ball when trying to explain your genes

Explaining, not just predicting, drives interest in personal genomics. Meisel SF, Carere DA, Wardle J, Kalia SS, Moreno TA, Mountain JL, Roberts JS, Green RC; PGen Study Group. Genome Med. 2015;7(1):74. doi: 10.1186/s13073-015-0188-5. eCollection 2015. BACKGROUND: There is a widespread assumption that risk prediction is the major driver of customer interest in personal genomic testing...

Genes and response to interferons

Bertoli D, Serana F, Sottini A, Cordioli C, Maimone D, Amato MP, Centonze D, Florio C, Puma E, Capra R, Imberti L.Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G&C Polymorphism at Position -174 of the IL-6 Promoter Gene.PLoS One. 2015;10(8):e0135441 One of the most common adverse event of...

Translate

Categories

Recent Posts

Recent Comments

Archives